TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10892523

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle self‐management program (very low‐fat vegetarian diet, stress‐management training, exercise, group support, and smoking cessation)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle self‐management program
Number of subjects: 28
Study: 8808432

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 600 mg orally daily for 4 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 36
Study: 8403157

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg.kg‐1) premedication, 10 min interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg.kg‐1) premedication, 20 min interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg.kg‐1) premedication, 30 min interval
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg.kg‐1) premedication, all groups
Number of subjects: 30
Study: 2432845

Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg daily for 12 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg daily for 12 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 30
Study: 28967769

Group type: COMPARATOR
Intervention: Computer-generated feedback letters (CO)
Number of subjects: 961

Group type: COMPARATOR
Intervention: In-person counseling (PE)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Assessment only (AO)
Number of subjects: 961
Study: 26818228

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 4000 International Units daily for 16 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 2000 International Units daily for 16 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 64
Study: 25076139

Group type: EXPERIMENTAL
Intervention: Oxidised cellulose powder
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-absorbable packing
Number of subjects: 50
Study: 22735040

Group type: EXPERIMENTAL
Intervention: Financial incentive version of smoking cessation treatment costing $750 per success
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Treatment version of smoking cessation
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Medication version of smoking cessation
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Overall support for all smoking cessation treatments
Number of subjects: 1010
Study: 20448287

Group type: EXPERIMENTAL
Intervention: 50 mg weekly subcutaneous etanercept added to previous DMARD treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MRI joint synovitis added to tenosynovitis scores
Number of subjects: 31

Group type: COMPARATOR
Intervention: Previous DMARD therapy
Number of subjects: 31
Study: 17943363

Group type: EXPERIMENTAL
Intervention: Carbon dioxide at room temperature
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carbon dioxide at body temperature
Number of subjects: 30
Study: 15800228

Group type: EXPERIMENTAL
Intervention: Gabapentin-morphine combination
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 12858482

Group type: EXPERIMENTAL
Intervention: Propess
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 10609722

Group type: EXPERIMENTAL
Intervention: Inflatable obstetric belt
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 500
Study: 8936753

Group type: EXPERIMENTAL
Intervention: Small group treatment (3-4 patients)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Large group treatment (7-8 patients)
Number of subjects: 42
Study: 1826095

Group type: EXPERIMENTAL
Intervention: Heparin administration pre-dialysis
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Heparin assay methods (amidolytic assay and Heptest)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Heparin levels
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fibrin clot formation marker (FPA)
Number of subjects: 6
Study: 7091478

Group type: EXPERIMENTAL
Intervention: Quantity-Frequency (QF) method
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Time-Line (TL) method
Number of subjects: 40
Study: 30683848

Group type: EXPERIMENTAL
Intervention: Lean Fish (LF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fatty Fish (FF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Camelina Sativa Oil (CSO)
Number of subjects: 72
Study: 29524536

Group type: EXPERIMENTAL
Intervention: FENO-guided asthma management
Number of subjects: 179
Study: 27377073

Group type: EXPERIMENTAL
Intervention: Short-cycle therapy (SCT) (5 days on, 2 days off ART)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Continuous therapy (CT) (daily ART)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: SCT
Number of subjects: 199

Group type: COMPARATOR
Intervention: CT
Number of subjects: 199
Study: 25562034

Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanic acid (500/125 mg three times daily) for 7 days combined with prednisolone (30 mg/day for 7 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for 7 days combined with prednisolone (30 mg/day for 7 days)
Number of subjects: 35
Study: 21438715

Group type: EXPERIMENTAL
Intervention: Pre-clinical research using dogs with intervertebral disk herniation to assess efficacy of candidate therapeutics.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reproducible model of spinal cord injury in rodents for discovery.
Number of subjects: 0
Study: 19401897

Group type: EXPERIMENTAL
Intervention: Cold-water immersion therapy at 10 degrees C for 10 minutes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study: 17649644

Group type: EXPERIMENTAL
Intervention: Irinotecan plus fuorouracil and leucovorin with thalidomide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Irinotecan plus fuorouracil and leucovorin without thalidomide
Number of subjects: 32
Study: 15249584

Group type: EXPERIMENTAL
Intervention: Chemotherapy (fluorouracil and levamisole)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Chemotherapy and Radiation Therapy (chemoRT)
Number of subjects: 222
Study: 11228276

Group type: EXPERIMENTAL
Intervention: Reviparin twice daily
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Reviparin once daily
Number of subjects: 961

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 961
Study: 10023335

Group type: COMPARATOR
Intervention: Hybrid capture I (HC I)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hybrid capture II (HC II)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hybrid capture II (HC II) with a ratio of cervical sample to normal control of > 200
Number of subjects: 42
Study: 8150601

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy in cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy in repeat studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy in non-cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy for specific disease entities in non-cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy for suspected metastases in non-cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy for evaluation of X-ray abnormalities in non-cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clarity of diagnostic question in non-cancer patients
Number of subjects: 0
Study: 3220008

Group type: EXPERIMENTAL
Intervention: Sulbactam 1g plus ampicillin 2g (14 women)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cefoxitin 2g (8 women)
Number of subjects: 22
Study: 31900982

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment ± endovascular therapy followed by anticoagulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (age-matched BCS patients presenting with ascites, no bleeds)
Number of subjects: 40
Study: 30476963

Group type: EXPERIMENTAL
Intervention: 0.1-mL fractional dose intradermally
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.5-mL standard dose subcutaneously
Number of subjects: 75
Study: 28209169

Group type: EXPERIMENTAL
Intervention: Vascular Impulse Technology (VIT) system
Number of subjects: 280

Group type: COMPARATOR
Intervention: Elevation
Number of subjects: 280
Study: 26427279

Group type: EXPERIMENTAL
Intervention: 10 mg of torasemide
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 50 mg of spironolactone
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Co-administration of 100 mg spironolactone and 20 mg furosemide
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo (implied for chronic intake of torasemide)
Number of subjects: 1
Study: 21946548

Group type: EXPERIMENTAL
Intervention: Daily use of travoprost 0.004%
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alternate day use of travoprost 0.004%
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of daily vs alternate day use
Number of subjects: 14
Study: 20107201

Group type: EXPERIMENTAL
Intervention: Cyclosporine (oral bioavailability)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Cyclosporine (gelatin capsule microemulsion formulation)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: NR1I2 genotype (g.‐25385C‐g.‐24381A‐g.‐205_‐200GAGAAG‐g.7635G‐g.8055C haplotype)
Number of subjects: 176
Study: 19736596

Group type: EXPERIMENTAL
Intervention: Green tea meal replacement formula
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 120
Study: 17127551

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment for ADHD and cocaine dependence
Number of subjects: 92

Group type: COMPARATOR
Intervention: Abstainers
Number of subjects: 92

Group type: COMPARATOR
Intervention: Consistent cannabis users
Number of subjects: 92
Study: 12768117

Group type: EXPERIMENTAL
Intervention: Hypertonic saline dextran (HSD) (250 mL)
Number of subjects: 230
Study: 10705267

Group type: EXPERIMENTAL
Intervention: EH 200 group (62 patients) using EH 200 microg/dose inhaler (1 inhalation q.i.d.)
Number of subjects: 185

Group type: COMPARATOR
Intervention: DH group (61 patients) using DH 200 microg/dose inhaler (1 inhalation q.i.d.)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: EH 400 group (62 patients) using EH 400 microg/dose inhaler (1 inhalation b.i.d.)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: EH groups (62 patients each)
Number of subjects: 185
Study: 9349931

Group type: EXPERIMENTAL
Intervention: 15-min i.v. infusion of 1 mg draflazine followed by continuous infusion of 1 mg.h‐1
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Continuous infusion of draflazine over a longer time period (e.g., 24 h)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 15-min i.v. infusion of 1 mg draflazine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Continuous infusion of draflazine
Number of subjects: 19
Study: 8477320

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment only for reflux grade III or less
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Surgery plus antibiotic treatment for reflux grade IV
Number of subjects: 93

Group type: COMPARATOR
Intervention: Antibiotic treatment alone for reflux grade IV
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Reimplantation for reflux grade V
Number of subjects: 93
Study: 3816528

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 40
Study: 31307494

Group type: EXPERIMENTAL
Intervention: Reactive focal mass drug administration (rfMDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education on rfMDA and malaria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived risk for malaria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misunderstandings about asymptomatic malaria
Number of subjects: 0
Study: 30672215

Group type: EXPERIMENTAL
Intervention: Yinqi Guiyuan needles therapy combined with moxibustion at Yongquan (KI 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam and oryzanol
Number of subjects: 100
Study: 27270872

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg/day equivalent to 70 mg curcumin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 0
Study: 24129359

Group type: EXPERIMENTAL
Intervention: Basic web-based weight loss program
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Enhanced web-based weight loss program
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Successful participants (weight loss ≥5%)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 268
Study: 22014381

Group type: EXPERIMENTAL
Intervention: Immediate Zoledronic Acid (ZOL) treatment (4 mg every 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed Zoledronic Acid (ZOL) treatment (4 mg every 6 months)
Number of subjects: 0
Study: 20401438

Group type: EXPERIMENTAL
Intervention: 0.1 mg rhTSH (group I, N = 8)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.01 mg rhTSH (group II, N = 6)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (group III, N = 8)
Number of subjects: 20
Study: 17206439

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 min at 60% maximal oxygen uptake)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral glucose ingestion (75 g) without exercise
Number of subjects: 11
Study: 14979604

Group type: EXPERIMENTAL
Intervention: Adicanil (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Commercially available preparation (reference formulation)
Number of subjects: 24
Study: 12621741

Group type: EXPERIMENTAL
Intervention: Three times a day administration of carbapenems (0.5 g x 3)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Twice a day administration of carbapenems (0.75 g x 2)
Number of subjects: 72
Study: 9818297

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg tablet) with food
Number of subjects: 9

Group type: COMPARATOR
Intervention: Amitriptyline (25 mg tablet) fasting
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nortriptyline (25 mg tablet) with food
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nortriptyline (25 mg tablet) fasting
Number of subjects: 9
Study: 7582060

Group type: EXPERIMENTAL
Intervention: Active antihypertensive treatment
Number of subjects: 15990
Study: 2476039

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg midazolam
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.15 ml/kg NaCl 0.9%
Number of subjects: 20
Study: 362999

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefazolin and Cephalothin
Number of subjects: 0
Study: 31842852

Group type: EXPERIMENTAL
Intervention: Local ingredients-based supplement (LIBS) - 100 g of LIBS plus 25.2 g of sugar with 8 ml oil
Number of subjects: 324

Group type: COMPARATOR
Intervention: Corn-soya blends plus (CSB+) - 150 g of CSB+ with 16 ml of oil
Number of subjects: 324
Study: 28577369

Group type: EXPERIMENTAL
Intervention: Four-hour drainage clamping technique
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-clamping drainage technique
Number of subjects: 64
Study: 25836004

Group type: EXPERIMENTAL
Intervention: Translation treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Controlled tipping treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 18
Study: 23657969

Group type: EXPERIMENTAL
Intervention: Tibetan Sound Meditation (TSM) - two weekly sessions for 6 weeks
Number of subjects: 47
Study: 22030296

Group type: EXPERIMENTAL
Intervention: Depression prevention program for girls
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group for girls
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Depression prevention program for boys
Number of subjects: 301
Study: 19174617

Group type: EXPERIMENTAL
Intervention: Haloperidol (10 microg/kg) plus ondansetron (0.1 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Haloperidol (10 microg/kg)
Number of subjects: 60
Study: 17597037

Group type: EXPERIMENTAL
Intervention: Postoperative first day IL-6 levels
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Preoperative hsCRP levels
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Postoperative first day hsCRP levels
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intensive care unit stay
Number of subjects: 49

Group type: COMPARATOR
Intervention: Endotracheal intubation times
Number of subjects: 49
Study: 16028651

Group type: EXPERIMENTAL
Intervention: 1 ml 30% glucose
Number of subjects: 70

Group type: COMPARATOR
Intervention: 1 ml placebo solution (sterile water)
Number of subjects: 70
Study: 11799368

Group type: EXPERIMENTAL
Intervention: Inhaled hydrofluoroalkane triamcinolone acetonide (450 microg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral montelukast (10 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10522838

Group type: EXPERIMENTAL
Intervention: Repaglinide (0.25-4.0 mg preprandially)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repaglinide (0.25-8.0 mg preprandially)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5-4.0 mg preprandially)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphonylureas (glibenclamide, glipizide, gliclazide)
Number of subjects: 0
Study: 7536152

Group type: EXPERIMENTAL
Intervention: Tasks involving number comprehension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tasks involving recognition of mathematical symbols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tasks involving the calculation process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tasks involving the spatial component
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest periods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tasks
Number of subjects: 0
Study: 2039041

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study: 7367848

Group type: EXPERIMENTAL
Intervention: Specific hyposensitization treatment with semi-depot extracts
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Specific hyposensitization treatment for asthma
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Specific hyposensitization treatment for rhinitis
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Specific hyposensitization treatment for conjunctivitis
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Second and third courses of treatment
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Generalized allergic reactions during hyposensitization
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Local reactions during hyposensitization
Number of subjects: 821

Group type: COMPARATOR
Intervention: Global results of 409 hyposensitization treatments by outside practitioners
Number of subjects: 821
Study: 31053570

Group type: EXPERIMENTAL
Intervention: pdFVIII
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FL-rFVIII
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of pdFVIII and FL-rFVIII
Number of subjects: 0
Study: 29089038

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200 mg) and ascorbic acid (2 g) intravenously, administered 2 hours before, and at 10 and 18 hours after contrast infusion
Number of subjects: 124

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine and ascorbic acid
Number of subjects: 124
Study: 25582984

Group type: EXPERIMENTAL
Intervention: Low-dose levonorgestrel (LNG) and ethinyl estradiol (EE) contraceptive patch (CP, Twirla™)
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Low-dose combination oral contraceptive (COC)
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Laboratory assessments for both groups
Number of subjects: 1328
Study: 23350584

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Multiple lines of trastuzumab
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lapatinib after trastuzumab
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lapatinib after diagnosis of brain metastases (BM)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Positive estrogen receptor (ER) status
Number of subjects: 201
Study: 21314437

Group type: EXPERIMENTAL
Intervention: Alcaftadine ophthalmic solution 0.25%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcaftadine ophthalmic solution (various concentrations 0.05%-0.5%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcaftadine 0.25% ophthalmic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tears Naturale II (placebo)
Number of subjects: 0
Study: 19223168

Group type: EXPERIMENTAL
Intervention: Pre-loading with 500 mL of 6% hetastarch intravenously
Number of subjects: 46

Group type: COMPARATOR
Intervention: Co-loading with 500 mL of 6% hetastarch intravenously
Number of subjects: 46
Study: 17415637

Group type: EXPERIMENTAL
Intervention: Oral erythromycin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral omeprazole without erythromycin
Number of subjects: 20
Study: 15155436

Group type: EXPERIMENTAL
Intervention: Diclofenac patch
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 120
Study: 11589866

Group type: EXPERIMENTAL
Intervention: Travoprost 0.0015%
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 801

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 801

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 801
Study: 9699197

Group type: EXPERIMENTAL
Intervention: Androgen gel (group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo gel (group P)
Number of subjects: 39